Palvella Therapeutics, Inc. Repayments of Debt
Palvella Therapeutics, Inc. (PVLA) reported Repayments of Debt of $1.16 million for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2017-03-30
- Palvella Therapeutics, Inc. repayments of debt for the quarter ending 2015-12-31 was $0.00.
- Palvella Therapeutics, Inc. repayments of debt for the quarter ending 2015-09-30 was -$13.23K, a 125.19% decline year-over-year.
- Palvella Therapeutics, Inc. repayments of debt for the quarter ending 2015-06-30 was $43.37K.
- Palvella Therapeutics, Inc. repayments of debt for the quarter ending 2015-03-31 was $1.13M.
- Palvella Therapeutics, Inc. repayments of debt for fiscal 2015 was $1.16M, a 537.93% increase from fiscal 2014.
- Palvella Therapeutics, Inc. repayments of debt for fiscal 2014 was $181.51K.
| Period end | Repayments of Debt 3 month | Repayments of Debt 3 month as first filed | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$13.23K derived: sum of 2 quarters · filed 2017-03-30 | $30.14K derived: sum of 3 quarters · filed 2017-03-30 | $1.16M 10-K · filed 2017-03-30 | |
| 2015-09-30 | -$13.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $30.14K derived: sum of 2 quarters · filed 2016-11-10 | $1.16M 10-Q · filed 2016-11-10 | $1.15M derived: sum of 4 quarters · filed 2016-11-10 | |
| 2015-06-30 | $43.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $1.17M 10-Q · filed 2016-08-11 | $1.16M derived: sum of 3 quarters · filed 2016-08-11 | $1.22M derived: sum of 4 quarters · filed 2016-08-11 | |
| 2015-03-31 | $1.13M 10-Q · filed 2016-05-12 | $1.00M 10-Q · filed 2015-05-14 | $1.12M derived: sum of 2 quarters · filed 2016-05-12 | $1.17M derived: sum of 3 quarters · filed 2016-05-12 | |
| 2014-12-31 | -$7.91K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $44.62K derived: sum of 2 quarters · filed 2016-03-23 | $181.51K 10-K · filed 2016-03-23 | ||
| 2014-09-30 | $52.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $189.42K 10-Q · filed 2015-11-13 | |||
| 2014-06-30 | $136.90K 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |